Skip to main content

Table 1 Percentage of patients with adapted JIA ACR (aacr) response and inactive disease

From: PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis

CAN, N = 178

N(%)

Aacr30

Aacr50

Aacr70

Aacr90

Aacr100

Inactive disease

Week 2

142 (80%)

125 (70%)

102 (57%)

65 (37%)

38 (21%)

36 (20%)

Week 12

125 (70%)

122 (69%)

108 (61%)

87 (49%)

54 (30%)

50 (28%)

  1. Data from missing patients not shown; aacr response = ACR response level plus absence of fever
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096